Cristalens Turned an EIC Accelerator Grant Into Eye Lens Sales

Cataract surgery replaces the clouded natural lens of the eye with a plastic implant, and almost every patient who gets a standard implant leaves the operating room needing reading glasses. Cristalens Industrie, a manufacturer of these intraocular lenses in Lannion, Brittany, sells a different answer: two complementary implants, one tuned for intermediate distances and one for near vision, placed in a patient's two eyes so that the brain combines them into continuous sight from about 40 to 90 centimetres. The European Commission selected the project, SYMBIOSE, in the March 2020 cut-off of the EIC Accelerator pilot, with grant-only funding. Cristalens Industrie is the only company listed for the project.

The grant was €1,598,459 towards a total cost of €2,283,528.75, for a project that ran from 1 October 2020 to 31 March 2024, according to CORDIS. Over roughly the same period the company's revenue doubled, from €9.01 million in 2020 to €18.32 million in 2024, according to filed accounts in the INPI ratios dataset. The 2024 figure matches the French company register and societe.com. The clinical programme at the heart of the grant is a different story.

Where Cristalens Stands Now

Cristalens Industrie is an active, profitable manufacturer. It filed its accounts for 2025 in August 2026 and registered a capital increase in October 2026, raising its share capital to €4,676,872.56, according to BODACC notices. An earlier increase, to €4,270,568.40, was decided on 18 April 2025, according to a legal notice reproduced by societe.com, which also lists auditors' reports on contributions in kind from July 2025. Who contributed what is not public. BODACC records no insolvency proceedings.

The company's history goes back to 1994, when Alain Brocq, formerly of Smith & Nephew's ophthalmology division, founded a French distributor of imported lenses, according to the company. Manufacturing in Lannion started in 2004 on a site with available clean rooms, with support from the town and from Alcatel, Denis Delage told the French patent office INPI in October 2024, when the company was a finalist in its innovation awards. In that interview the company said 60% of its revenue came from exports to more than fifty countries, and declared an R&D budget of €920,000 for 2023, seven patents and sixteen trademarks.

The latest public project is industrial. In December 2025 the company showed the prefect and the president of the Brittany region a new process that moulds a finished lens by injecting liquid material between two shells, supported by a €500,000 repayable advance from the France 2030 investment plan, paid in two steps in January 2025 and September 2027, according to a company release. The company says the process should cut raw material use by about 50% and add capacity for up to 500,000 lenses a year, aimed at price-sensitive markets such as China and Latin America. That is a target, not a result.

The Technology: Two Different Lenses, One Pair of Eyes

Patients who want to drop their glasses after cataract surgery are usually offered a multifocal or extended-depth-of-focus lens, which splits incoming light into several focal points in each eye at the cost of some contrast and, for some patients, halos at night. Cristalens took another route. Its Artis Symbiose Mid lens favours intermediate vision and the Symbiose Plus lens favours near vision; implanted one in each eye, they are designed to give a continuous binocular range from far to about 30 centimetres, its optics researcher Fannie Castignoles told Healio in September 2019. The company patented the idea as "Binocular Phase Continuity", according to its CORDIS report.

The product therefore existed before the grant: it was presented to surgeons in 2019 with early results from a clinic in Murcia, Spain. What the EIC paid for was the evidence and the industrial base to sell it widely.

Independent surgeons have since tested the near-vision lens. A South Korean study in Scientific Reports in May 2023 compared 26 patients given Symbiose Plus in both eyes with 22 patients given the company's standard monofocal lens: near and intermediate vision were significantly better with Symbiose, while optical quality measures favoured the monofocal lens. The authors reported no funding and no competing interests. A second Korean study, from Yonsei University in International Ophthalmology in 2024, compared Symbiose Plus with Johnson & Johnson's Tecnis Synergy in 48 eyes each: distance and near vision were similar, Synergy was better at intermediate distance, and Symbiose scored better on optical quality and patient satisfaction. Neither study tested the paired Mid and Plus system the grant was built around.

What the EIC Project Promised, and What CORDIS Shows

The CORDIS objective set four work packages: demonstrate the performance of the complete system in 300 patient cases, prepare a manufacturing scale-up to meet demand, convince the scientific and medical community, and remove regulatory barriers while securing intellectual property. CORDIS files the project under the SME Instrument phase 2 scheme of the Horizon 2020 call, the format the EIC Accelerator pilot used.

The only published periodic report, covering October 2021 to March 2024, is thin and reads as if it was written early. It says three clinical studies had been launched, the first "with already 10 patients enrolled", and still uses the future tense for the project's end: "By 2024, a total of 6 clinical studies will be launched", and Symbiose "will be registered and distributed in approximately 55 countries". At the time of writing it said the lens was registered and distributed in 27 countries and that the first patent had been filed in 12 countries worldwide and 15 in Europe. CORDIS lists one peer-reviewed paper and several congress presentations as results, mostly by the Murcia team.

ClinicalTrials.gov lists two Cristalens-sponsored trials, both registered in March 2024, as the project ended: a comparison of three lenses in Murcia, started in April 2021 with an estimated 84 patients, and a comparison with the PanOptix lens at Heidelberg University, started in July 2022 with an estimated 50 patients. Both aim to show that Symbiose is superior. Their status has not been updated since March 2024, their estimated completion dates have passed, and no results are posted. Together they plan 134 patients, fewer than half the 300 the project promised.

1. Clinical performance of the full system in 300 patientsNot achievedThe final report cites 10 enrolled patients; the two registered trials plan 134 and have posted no results.
2. Six clinical studies launched by 2024Not achievedThe report names three; ClinicalTrials.gov lists two.
3. Manufacturing scale-upPartlyRevenue doubled by 2024; the new moulding process is funded until 2027 and not yet in production.
4. Convince the scientific and medical communityDeliveredCongress papers and two independent Korean studies of Symbiose Plus.
5. Registration in about 55 countriesPartly27 countries in the CORDIS report; no later Symbiose-specific figure is public.
6. Secure the intellectual propertyDeliveredPatent for the lens pair filed in 12 countries and 15 European states.

The result is a commercial success built on a clinical programme that fell short of its promise. The grant was for evidence, and the large, multi-study dataset that was supposed to convince surgeons worldwide has not appeared in public.

The Money

Cristalens has been profitable in every year of the INPI series, which starts in 2015. Revenue was flat at €9.04 million in 2019 and €9.01 million in 2020, then jumped 54% to €13.86 million in 2021, the first full year of the EIC project, and kept rising to €18.32 million in 2024. INPI's interviewer described the success of Artis Symbiose and several French and European grants as an accelerator of revenue. How much of the revenue comes from Symbiose itself is not public.

Earnings did not keep pace. Gross operating profit (EBE) peaked at €3.18 million in 2021 and fell to €815,824 in 2024, and net profit fell from €1,157,298 in 2022 to €460,013 in 2024, according to the INPI dataset. The register confirms the 2024 net result.

Cristalens Industrie does not appear among the 326 companies listed on the EIC Fund portfolio pages, which fits its grant-only award. No venture round has been reported; its growth appears to have been financed from operations, public grants and the capital increases noted above, whose investors are not named.

The 2026 Recall

On 13 March 2026 Cristalens Industrie issued a field safety notice recalling specific batches of its preloaded hydrophobic Artis PL E and Artis Symbiose lenses, after incident reports received worldwide between April 2025 and January 2026 of a whitish opalescence appearing in 10 implanted lenses between one day and five weeks after surgery, according to the company's letter. Five of the ten lenses had to be removed. The company put the incidence at 0.0038% of the preloaded hydrophobic lenses it sold in 2025 and said the root cause had not yet been established. France's medicines agency ANSM published the recall on 19 March 2026 under number R2606056. Two of the recalled batches are Symbiose Plus lenses, one of them a toric version for astigmatism. No later update on the cause has been published.

Why Europe Should Care

Cataract is among the leading causes of vision loss: 94 million people worldwide have distance vision impairment or blindness from it, and one in two people who need the operation do not have access to it, according to the World Health Organization, which calls the operation one of the most cost-effective in health care. The premium lenses Cristalens measures itself against in its trials, such as Tecnis Synergy from Johnson & Johnson, come from large non-European groups. A European manufacturer that controls its supply chain from raw polymer in Strasbourg to packaged lens in Lannion, as the company describes it, is the kind of medical device supplier the EU says it wants to keep.

The regulatory side matters as much. On 16 December 2025 the Commission proposed to simplify the Medical Devices Regulation, with fee cuts for small manufacturers and timelines for conformity assessments, according to Baker McKenzie and EPR. Clinical evidence is the currency of that system, which is why the missing SYMBIOSE trial results matter beyond one company.

The Verdict

Cristalens Industrie has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.